Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost-A Multicentre, Retrospective Study

• Published in: International journal of molecular sciences 2023-03, Vol.24 (7), p.6434
• Main Authors: Camara, Raquel Paulinetti, Coelho, Francisco das Neves, Cruz-Martins, Natália, Marques-Alves, Patrícia, Castro, Graça, Baptista, Rui, Ferreira, Filipa
• Format: Article
• Language: English
• Subjects: Aggregation; Antihypertensive Agents - adverse effects; Bacteria; Biofilms; Blood platelets; bloodstream infection; Care and treatment; Catheters; Chronic illnesses; Complications and side effects; Epoprostenol - adverse effects; Familial Primary Pulmonary Hypertension; Gram-negative bacteria; Gram-positive bacteria; Health services; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary - chemically induced; Hypertension, Pulmonary - drug therapy; Iloprost - adverse effects; Incidence; Infection; Intravenous administration; Microorganisms; Mortality; Patients; Prostacyclin; pulmonary arterial hypertension; Pulmonary hypertension; Retrospective Studies; Sepsis - drug therapy; Solvents; Staphylococcus infections; survival; synthetic prostacyclin analogs; Virulence
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24076434

Intravenous synthetic prostacyclin analogs (iPCAs), such as epoprostenol, treprostinil and iloprost have been widely used for the treatment of pulmonary arterial hypertension (PAH). Despite having good outcomes, continuous infusion of iPCAs has been associated with some adverse effects. Bloodstream infection (BSI) is one of the most severe complications, although poorly recognized, especially under iloprost administration, which few studies have addressed. This study aimed to compare the BSI incidence rates between intravenous iloprost and epoprostenol administration. Patients with pulmonary hypertension (PH) functional class III or IV receiving intravenous iloprost or epoprostenol through Hickman catheter, between 2004 and 2019, were retrospectively selected from two PH treatment centers. From a total of 36 patients (13 for iloprost and 23 for epoprostenol), 75% ( = 27) fulfilled the PAH criteria, mainly belonging to the idiopathic group. Overall BSI rate was 1.5/1000 days of treatment (3.38 and 0.09/1000 days for iloprost and epoprostenol, respectively). Patients receiving iloprost were at a higher risk of developing BSI than those receiving epoprostenol (HR: 12.5; 95% CI: 1.569-99.092). A higher mortality rate from BSI was also identified in the iloprost group ( = 0.04). Twenty-seven patients developed BSI, with 92% of them requiring hospitalization. A total of 29 agents were found, 10 Gram-positive (mainly ; = 5) and 19 Gram-negative (mainly ; = 6) bacteria. Iloprost administration was linked to a significantly higher incidence of BSI, worse prognosis, and more BSI-related deaths than epoprostenol. BSI due to Gram-negative, commensal, low-virulence bacteria was also higher in the iloprost group. In short, physicians should be aware when prescribing iPCA to guarantee their patients' safety and best medical care.